You searched for "intracameral"
Mucormycosis: In conversation with Dr Deepak Haldipur and Dr Aditya Moorthy
15 July 2021
| Deepak Haldipur, Aditya Moorthy, Sunil Narayan Dutt (Dr Prof)
|
EYE - Orbit, EYE - Oculoplastic, EYE - General
COVID-19 has ravaged the world in the past 18 months. The second wave in many countries was deadlier than the first. Mucormycosis, infamously labelled ‘the black fungus’ has affected some countries, such as India, in epidemic proportions within this COVID...
Two-year results of a T&E aflibercept regime in caucasian PNV
4 October 2023
| Su Young
|
EYE - Vitreo-Retinal
This a retrospective study examining two-year outcomes of patients with pachychoroid neovasculopathy (PNV) treated with a treat and extend (T&E) regimen of intravitreal aflibercept. The mean age was 63.84 ± 7.92 years with nine males (35%) and 17 females (65%)....
Managing a dislocated intraocular lens
A 70-year-old male patient is referred from the optician with a history of onset of double vision and examination shows a dislocated / subluxated IOL. How will you manage this patient? If the double vision is causing serious concern to...A Multidisciplinary Approach to Neovascular Glaucoma in a Patient with Waldenström’s macroglobulinemia
1 December 2013
| Inderpaul S Sian, Karl Whittaker
An 84-year-old Caucasian male attended eye casualty with a four month history of reduced vision, a dull ache and photophobia in both eyes. He had also reported dizziness, weakness and intermittent epistaxis in the nine months prior to presentation. There...
Non-arteritic anterior ischaemic optic neuropathy (NA-AION): a review
1 February 2017
| James F (Barry) Cullen
|
EYE - Neuro-ophthalmology
Ischaemic optic neuropathy (ION) is the commonest adult optic neuropathy encountered today in our ageing population, is a common cause of irreversible visual loss and is usually associated with underlying vascular disease. The condition is classified as follows: (a) Anterior...
Retrospective review of visual outcomes in Idiopathic intracranial hypertension (IIH)
1 December 2022
| Claire Howard
|
EYE - Neuro-ophthalmology
|
Idiopathic intracranial hypertension, Pseudotumor cerebri, visual outcome
Idiopathic intracranial hypertension (IIH) is a clinical syndrome characterised by headache and papilloedema that can lead to significant visual morbidity. IIH is diagnosed by the modified Dandy criteria, which include normal neuroimaging and cerebrospinal fluid (CSF) composition, high CSF opening...
How common is empty sella in neuro-ophthalmology patients not suspected of raised intracranial pressure
28 February 2025
| Lauren R Hepworth
|
EYE - Neuro-ophthalmology
The study aimed to assess how common the presence of empty / partially empty sella is amongst neuro-ophthalmology patients undergoing magnetic resonance imaging (MRI) excluding for papilledema and raised intracranial pressure (ICP). The study retrospectively reviewed case records of consecutive...
An update on inherited retinal disorders (part 2): Approaches to therapy for IRDs
1 December 2016
| Stacey Strong, Michel Michaelides (Prof)
|
EYE - Vitreo-Retinal
Part 1 of this topic can be found here There are currently no proven cures for inherited retinal disease (IRD). However, multiple avenues of research are being investigated to better understand disease mechanisms and trial potential therapies that may slow...
Papilloedema: an update
1 June 2016
| James F (Barry) Cullen
|
EYE - Neuro-ophthalmology
Some readers may have seen a recent report in the national newspapers of the case of a teenage girl with persistent severe headache associated with a fatal brain tumour having been undiagnosed despite many consultations with her medical advisers. It...
Introduction of the Mydriasert insert at the Manchester Royal Eye Hospital
The authors report on a study to examine the effects of the Mydriasert insert on time, effects, patient comfort and tolerability at Manchester Royal Eye Hospital. Mydriasert is an insoluble ophthalmic insert indicated for mydriasis prior to ophthalmic surgery, which...Sustainability in eyecare: Intraocular gases and the climate emergency
In 2020 the NHS became the first national health system to commit to delivering ‘net zero’ carbon emissions by 2040. The author investigates how the impact of ophthalmic surgery can be reduced. Medical gases have been used in ophthalmic surgery...Cutting-edge practice in glaucoma care: what, how and why?
1 April 2016
| Nick Strouthidis, Winifred Nolan, Keith Barton
|
EYE - Glaucoma
More effective treatments and drug delivery modalities, implantable minimally invasive glaucoma surgical (MIGS) devices, as well as accelerating clinical research programmes, will transform the surgical and clinical management of glaucoma in the near future. There is also an ever-greater emphasis...
